BioSpace News Archive

The Heart Failure Society of America (HFSA) is pleased to announce the Late Breaking Clinical Trials coming to its Annual Scientific Meeting (ASM), which will take place September 30 – October 3, 2022, at the Gaylord National Harbor, just outside of Washington, DC.

Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, Sept. 13, 2022. Anat Ashkenazi, Lilly’s senior vice president and chief financial officer, will participate in a fireside chat at 11:10 a.m., Eastern time.

On August 30, 2022, Broncus (02216.HK), the leader in the field of interventional pulmonology in China, reported its interim result for the six months ended June 30, 2022 (the “Reporting Period”).

Harbour BioMed (“HBM”, or the “Company"; HKEX: 02142), today announced its interim results for the six months ended June 30, 2022.

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that it has received emergency use authorization from the U.S. Food and Drug Administration for its BA.4/.5 Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222.

Marvel Biosciences Inc. (TSXV: MRVL) (the “Company” or “Marvel”) highlights recent research indicating a link between non-alcoholic steatohepatitis (NASH) and Alzheimer’s Disease (AD), two programs its lead asset, MB-204 are targeting.

Positive preclinical data in Science Translational Medicine, published , outlines the mechanisms of the three proteins, which have been shown to restore heart function following a heart attack in mice.

Calgary, Alberta--(Newsfile Corp. - August 31, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) received numerous enquiries about the press release of August 30, 2022. This press release details the results in a table format and clarifies a misprint.

Zealand Pharma A/S announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital.

Aquestive Therapeutics, Inc. (Nasdaq: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, announced today that the management team will participate in the two upcoming investor conferences in September.